APR is a Swiss independent pharma company focused on development and global commercialization of innovative, research-driven products designed to address unmet needs in specialized therapeutic areas and rare diseases.
APR combine pharmaceutical development expertise with proprietary drug delivery technologies to realize solutions that meaningfully improve the lives of people with rare diseases and empower families through novel approaches to disease management.
A diverse and balanced portfolio of revenue-generating products in all major markets is complemented by a robust pipeline of innovative products at different stages of development for the treatment of recessive metabolic disorders, as well as rare dermatological and ocular diseases.
Products are directly commercialized by APR through inhouse sales and marketing teams in strategically important countries across Europe and a growing worldwide network of commercial partners.
APR combine pharmaceutical development expertise with proprietary drug delivery technologies to realize solutions that meaningfully improve the lives of people with rare diseases and empower families through novel approaches to disease management.
A diverse and balanced portfolio of revenue-generating products in all major markets is complemented by a robust pipeline of innovative products at different stages of development for the treatment of recessive metabolic disorders, as well as rare dermatological and ocular diseases.
Products are directly commercialized by APR through inhouse sales and marketing teams in strategically important countries across Europe and a growing worldwide network of commercial partners.
Location: Switzerland, Ticino, Balerna
Employees: 11-50
Founded date: 1990
Investors 1
| Date | Name | Website |
| - | HBM Partne... | hbmpartner... |
Mentions in press and media 5
| Date | Title | Description |
| 13.05.2021 | Initiated clinical trial with novel nasal spray codenamed APR-AOS2020 in patients with mild COVID-19 | Product recently cleared in EU as Class III medical device BALERNA, Switzerland, May 13, 2021 /PRNewswire/ -- APR Applied Pharma Research s.a. (APR), a leader in the development of pharmaceutical drug delivery technologies and systems and i... |
| 12.05.2021 | Initiated clinical trial with novel nasal spray codenamed APR-AOS2020 in patients with mild COVID-19 | |
| 04.05.2021 | RELIEF THERAPEUTICS HOLDING AG Relief Therapeutics : and Applied Pharma Research (APR) Sign Binding Term Sheet for to Acquire All Outstanding Shares of APR | Acquisition would further diversify Relief's pipeline with both commercial products and clinical-stage programs Geneva and Balerna, Switzerland, May 4, 2021 - RELIEF THERAPEUTICS Holding AG (SIX: RLF, OTCQB: RLFTF)('Relief'), a biopharmaceu... |
| 31.03.2015 | Applied Pharma Research Receives Minority Investment from HBM Partners | APR Applied Pharma Research s.a., a Balerna, Switzerland-based developer of science driven, patent protected Healthcare products, received a minority investment from HBM Partners. The amount of the deal was not disclosed. As part of it, Val... |
| 06.06.2012 | Bright Technologies Fund Invests in APR Applied Pharma Research |